• Explore /
  • Poster
  • / Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.

Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.

Abstract Poster

Authors

null

Roberto Pili

Indiana University, Indianapolis, IN

Roberto Pili , Nabil Adra , Nur Damayanti , Theodore F. Logan , Vivek Narayan , Paul Monk III, S Dropcho , Lina M Sego , Hao Liu , Sandra K. Althouse , Naomi B. Haas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03024437

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5064)

DOI

10.1200/JCO.2020.38.15_suppl.5064

Abstract #

5064

Poster Bd #

133

Abstract Disclosures

Similar Posters

First Author: Roberto Pili

First Author: Roberto Pili

First Author: Daneng Li

First Author: Takeshi Terashima